Innate Pharma

[beursfre]

Bied momenteel boven de 7.6...

halted
bied boven de 8
in de laat zal het straks uitgeput zijn

[beursfre]

Amerika 10,91 dollar
das 9€…..

traders wss… opletten dus…

[Ivel]

Proficiat aan degene die long zitten
Ik was helaas uitgestapt vorig jaar nadat een belangrijk partnership afsprong, zo zie je maar: geduld loont!

[beursfre]

we moeten aan 7€ sluiten wss

[Brammeke]

tja die heb ik beetje te vroeg verkocht.

kga geen advies geven
maar morgen is er nog een voorstelling van iets…
en men verwacht zelfde nieuws


nieuws vandaag Astra Zenica start een Phase 3 ism Innate

Tja, "dom" mijnentwege. Loop ze nu ook niet meer achterna.
Laat ze "gaan".
In' t verleden "geweldige" zaken gedaan met biotech ( o.a ablx, argx!!, glpg ook nog, en nog andere). En wie weet wat komt er nog.
Kan niet altijd feest zijn eh. Ik vergeet niet dat ik hier toch nog "winstje" heb behaald.

[Wimpie85]

tja die heb ik beetje te vroeg verkocht.

kga geen advies geven
maar morgen is er nog een voorstelling van iets…
en men verwacht zelfde nieuws


nieuws vandaag Astra Zenica start een Phase 3 ism Innate

Tja, "dom" mijnentwege. Loop ze nu ook niet meer achterna.
Laat ze "gaan".
In' t verleden "geweldige" zaken gedaan met biotech ( o.a ablx, argx!!, glpg ook nog, en nog andere). En wie weet wat komt er nog.
Kan niet altijd feest zijn eh. Ik vergeet niet dat ik hier toch nog "winstje" heb behaald.

Ik zit te wachten op Confo Therapeutics, maar geen idee of & wanneer die naar de beurs trekken. Zitten momenteel nog steeds in de pre-klinische fase natuurlijk, dus kan nog wel enkele jaartjes op zich laten wachten.

Met Ablynx ook een superzaak gedaan, GLPG was dan weer iets minder.

[Brammeke]

tja die heb ik beetje te vroeg verkocht.

kga geen advies geven
maar morgen is er nog een voorstelling van iets…
en men verwacht zelfde nieuws


nieuws vandaag Astra Zenica start een Phase 3 ism Innate

Tja, "dom" mijnentwege. Loop ze nu ook niet meer achterna.
Laat ze "gaan".
In' t verleden "geweldige" zaken gedaan met biotech ( o.a ablx, argx!!, glpg ook nog, en nog andere). En wie weet wat komt er nog.
Kan niet altijd feest zijn eh. Ik vergeet niet dat ik hier toch nog "winstje" heb behaald.

Ik zit te wachten op Confo Therapeutics, maar geen idee of & wanneer die naar de beurs trekken. Zitten momenteel nog steeds in de pre-klinische fase natuurlijk, dus kan nog wel enkele jaartjes op zich laten wachten.

Met Ablynx ook een superzaak gedaan, GLPG was dan weer iets minder.

Confo Therapeutics "volg" ik al "lang". Staan nog in de kinderschoenen.
Naar beurs ( nog niks over bekend) en dan nog heeeel lange tijd vooraleer......
Dit is iets van jaren.

Apitope misschien ook interessant.

Intussen op zoek naar anderen ( wie weet al gevonden : sorrento en arrowhead?)

[Innatenb]

Wat een prachtig beursdagje vandaag.. vanmorgen sublieme fase 2 Esmo gegevens van monalizumab icm durvalumab tov durvalumab SoC alleen.. en vanmiddag een persbericht dat Azn een fase 3 combinatiestudie aankondigd..(en bijkomende 100 miljoen mijlpaal als ik correct ben)
In Parijs een 16 miljoen aandelen verhandeld en in de VS is het hek helemaal van de dam.. net voor sluitingstijd zijn er maar liefst 65 miljoen aandelen over de toonbank gepasseerd

Morgen 18/9 is er inderdaad een presentatie over het Anket platform door Eric Vivier om 14u30..
Maar , maandag geeft Azn om 21u een investeerderspresentatie om de gegevens van esmo te bespreken. Ik loop misschien vooruit op de feiten maar zie ik hier een bruid wat naar het Azn-altaar loopt?

[manu47]

Paar dagen pull back maar we zijn weer vertrokken

[BioMark]

INNATE PHARMA THIRD QUARTER 2021 REPORT
Tue, 11/16/2021 - 07:00
Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca’s randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3
Pre-clinical data presented at SITC with Sanofi from the lead next-generation NK cell engager platform, ANKET™ targeting CD123 in acute myeloid leukemia
Cash position of €141.8 million as of September 30, 2021
Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months of 2021.

“In the period, we continued to execute against our strategic priorities as we reported readouts from two of our partnered portfolio programs. This included randomized Phase 2 data for monalizumab in combination with durvalumab in unresectable, Stage III NSCLC as well as pre-clinical data from our lead ANKET molecule targeting CD123 in acute myeloid leukemia. These readouts continue to set the stage for delivering both near and long-term value, while also highlighting the strength and depth of our core R&D efforts,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “Looking ahead, we will continue to advance our lacutamab development program and move our early-stage R&D activities towards the clinic with our next generation ANKET platform. We also look forward to seeing AstraZeneca’s upcoming plans for monalizumab’s registrational study in unresectable, Stage III NSCLC, which further reinforces our strategy of building a sustainable business with a robust R&D engine.”

*****

Webcast and conference call will be held today at 2:00 p.m. CET (8:00 a.m. ET)

The live webcast will be available at the following link:
https://event.on24.com/wcc/r/3492971/A9 ... D3C27EC089

Participants may also join via telephone using the following dial in numbers:

France dial-in number: +33 8056 20 704

United States: +1 646 904 5544

All other locations: +1 929 526 1599

Access code: 043615

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website following the event.

*****


Pipeline highlights:
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:
In September, AstraZeneca presented a late-breaker abstract on the randomized COAST Phase 2 trial in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Congress. The presentation highlighted progression-free survival (PFS) and overall response rate (ORR) results for durvalumab in combination with monalizumab, Innate’s lead partnered asset, and oleclumab, AstraZeneca’s anti-CD73 monoclonal antibody. After a median follow-up of 11.5 months, the results of an interim analysis showed a 10-month PFS rate of 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone in unresectable, Stage III NSCLC patients following chemoradiation therapy. The results also showed an increase in the primary endpoint of confirmed ORR for durvalumab plus monalizumab over durvalumab alone (36% vs. 18%).
Based on the data, AstraZeneca announced plans to initiate a Phase 3 trial for both combinations of monalizumab or oleclumab plus durvalumab in the unresectable, Stage III NSCLC setting for patients who had not progressed after concurrent chemoradiation therapy.
Separately, AstraZeneca also announced that it is starting a Phase 2 clinical trial, NeoCOAST-2, that includes a treatment arm with durvalumab in combination with chemotherapy and monalizumab in resectable, early-stage NSCLC.
Innate will present data from the Phase 2 expansion cohort (‘cohort 3’), exploring the combination of monalizumab, cetuximab and durvalumab in first-line IO naïve patients with recurrent/metastatic squamous cell carcinoma of the head and neck, which was accepted as a mini oral presentation at the ESMO Immuno-Oncology (ESMO-IO) conference in December 2021.
Lacutamab (anti-KIR3DL2 antibody):
Two parallel clinical trials to study lacutamab in patients with KIR3DL2-expressing, relapsed/refractory peripheral T-cell lymphoma (PTCL) are initiating:
◦ Phase 1b trial: a Company-sponsored Phase 1b clinical trial to evaluate lacutamab as a monotherapy in patients with KIR3DL2-expressing relapsed PTCL.

◦ Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial: The Lymphoma Study Association (LYSA) plans to initiate an investigator-sponsored, randomized trial to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed/refractory PTCL.

ANKET™ (Antibody-based NK cell Engager Therapeutics):
IPH6101/SAR443579

In November Innate and Sanofi shared new data on IPH6101/SAR443579 at the Society for Immunotherapy of Cancer (SITC) conference. IPH6101/SAR443579 is the first NKp46/CD16-based NK cell engager using Innate’s proprietary ANKETTM multispecific antibody format that targets CD123 on acute myeloid leukemia (AML) cells and co-engages NKp46 and CD16a on NK cells.
IPH6101/SAR443579 demonstrated potent antitumor activity against AML cell lines and primary AML blasts, including those resistant to ADCC by a comparator anti-CD123 antibody. IPH6101/SAR443579 also promoted strong and specific NK-cell activation and induced cytokine secretion only in the presence of AML target cells. In addition, IPH6101/SAR443579 had sustained pharmacodynamic effects in non-human primates, combining efficient depletion of CD123-expressing cells with minor cytokine release and a favorable safety profile in comparison to T-cell engagers.
Tetra-specific ANKET

In September and November 2021, Innate also presented at the ESMO 2021 and SITC conferences respectively. Innate shared data from its tetra-specific ANKET molecule, which is the first NK cell engager technology to engage two NK cell activating receptors (NKp46 and CD16), a cytokine receptor (IL-2Rb) and a tumor antigen via a single molecule. In preclinical studies, the tetra-specific ANKET demonstrated in vitro the ability to induce human NK cell proliferation, cytokine production and cytolytic activity against cancer cells expressing the targeted antigen.
The tetra-specific ANKET also demonstrated in vivo anti-tumor efficacy in several tumor models, allowing regression of established tumors as well as control of metastasis, associated with increased NK cell infiltration, cytokine and chemokine production at the tumor site. ANKET also showed a pharmacodynamic effect, low systemic cytokine release and a manageable safety profile in non-human primates.
IPH5201 (anti-CD39):
AstraZeneca is conducting a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab. The data is expected to be presented in 2022.
IPH5301 (anti-CD73):
The Company is initiating an investigator-sponsored Phase 1 trial of IPH5301 in collaboration with the Institut Paoli-Calmettes.
Financial Results:
Cash, cash equivalents and financial assets of the Company amounted to €141.8 million as of September 30, 2021. At the same date, financial liabilities amounted to €16.1 million.

Revenues for the first nine months of 2021 amounted to €10.3 million (€33.6 million for the same period in 2020). For the nine-month period, ended September 30, 2021, revenue from collaboration and licensing agreements mainly results from the spreading of the payments received under our agreements with AstraZeneca and Sanofi.

https://www.innate-pharma.com/media/all ... 021-report